Hsp90 inhibitors in breast cancer: A systematic review

被引：59
|
作者：
Zagouri, Flora [1 ]
Sergentanis, Theodoros N. [1 ]
Chrysikos, Dimosthenis [2 ]
Papadimitriou, Christos A. [1 ]
Dimopoulos, Meletios-Athanassios [1 ]
Psaltopoulou, Theodora [3 ]
机构：
[1] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, Athens 11521, Greece
[2] Univ Athens, Sch Med, Hippocrateio Hosp, Propaedeut Surg Dept 1, Athens 11521, Greece
[3] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens 11521, Greece
来源：
BREAST | 2013年 / 22卷 / 05期
关键词：
Breast cancer; Hsp90; inhibitors; Tanespimycin; Alvespimycin; Retaspimycin; HEAT-SHOCK-PROTEIN; PHASE-I TRIAL; TANESPIMYCIN; 17-AAG; ANTITUMOR EFFICACY; DOSE-ESCALATION; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; HEAT-SHOCK-PROTEIN-90; TRASTUZUMAB; HYDROCHLORIDE; COMBINATION;
D O I：
10.1016/j.breast.2013.06.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: Pharmacological inhibition of Hsp90 shows great promise in breast cancer treatment. This is the first systematic review to synthesize all available data and to evaluate the efficacy and safety of Hsp90 inhibitors in breast cancer. Methods: This study was performed in accordance with the PRISMA guidelines. Eligible articles were identified by a search of MEDLINE and ClinicalTrials.gov databases, using a predefined combination of the terms "breast", "cancer", "Hsp90", "inhibitors". Results: Overall, 19 articles (190 patients) were eligible. The greatest clinical activity has been observed on the field of HER2-positive metastatic breast cancer. However, accumulating data suggest that Hsp90 inhibitors may play a significant role in the treatment of triple negative and aromatase inhibitor-resistant breast cancer. Conclusion: In the last decade, the development of Hsp90 inhibitors has moved forward rapidly; however, no phase III trials have been conducted and none agent has been approved for use in the clinical practice. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：569 / 578
页数：10
相关论文
共 50 条
  • [41] A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    Adeela Kamal
    Lia Thao
    John Sensintaffar
    Lin Zhang
    Marcus F. Boehm
    Lawrence C. Fritz
    Francis J. Burrows
    Nature, 2003, 425 : 407 - 410
  • [42] A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    Kamal, A
    Thao, L
    Sensintaffar, J
    Zhang, L
    Boehm, MF
    Fritz, LC
    Burrows, FJ
    NATURE, 2003, 425 (6956) : 407 - 410
  • [43] Targeting the Hsp90 Chaperone: Synthesis of Novel Resorcylic Acid Macrolactone Inhibitors of Hsp90
    Day, James E. H.
    Sharp, Swee Y.
    Rowlands, Martin G.
    Aherne, Wynne
    Workman, Paul
    Moody, Christopher J.
    CHEMISTRY-A EUROPEAN JOURNAL, 2010, 16 (09) : 2758 - 2763
  • [44] Associations of HSP90 Client Proteins in Human Breast Cancer
    Shipp, Christopher
    Watson, Kenneth
    Jones, Graham Lloyd
    ANTICANCER RESEARCH, 2011, 31 (06) : 2095 - 2101
  • [45] Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors
    Koay, Yen Chin
    Wahyudi, Hendra
    McAlpine, Shelli R.
    CHEMISTRY-A EUROPEAN JOURNAL, 2016, 22 (51) : 18572 - 18582
  • [46] Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
    Porter, James R.
    Fritz, Christian C.
    Depew, Kristopher M.
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (03) : 412 - 420
  • [47] Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells
    Vykuntham, Naga Gowthami
    Suran, Sourabh
    Siripini, Satish
    John, Samu
    Kumar, Pankaj
    Paithankar, Khanderao
    Subbarao, Sreedhar Amere
    TOXICOLOGY IN VITRO, 2020, 65
  • [48] Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy
    Abdullah, Omeima
    Omran, Ziad
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
  • [49] Hsp90 inhibitors target addiction to mutant oncoproteins in colorectal cancer
    Clarke, P. A.
    Welsh, L.
    Valenti, M.
    Eccles, S.
    Workman, P.
    EJC SUPPLEMENTS, 2008, 6 (12): : 47 - 47
  • [50] Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer
    McDonald, Edward
    Workman, Paul
    Jones, Keith
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (11) : 1091 - 1107
12345